Search results for "SKIN"

showing 10 items of 3630 documents

The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice.

2015

The new 2010 ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) criteria of Rheumatoid Arthritis recently published, have been released to classify and identify patients with early RA who could benefit from early therapy. They recommend anti-citrullinated protein antibody (ACPA) testing as an alternative criterion to Rheumatoid Factor (RF) and ACPA that were introduced together with the other classic criteria in a scoring system. We previously criticized these new criteria because of unavailable specificity and sensibility in the first paper, and the use of ACPA as dichotomous criterion (presence/absent) and alternatives to rheumatoid factor. Our previous work p…

musculoskeletal diseasesmedicine.medical_specialtyScoring systemEarly rheumatoid arthritiEarly TherapyPeptides CyclicSensitivity and SpecificityAntibodiesArthritis RheumatoidInternal medicineInternal MedicineMedicineRheumatoid factorHumansACR/EULAR criteriaskin and connective tissue diseasesIntensive care medicineSocieties Medicalbusiness.industryProbabilistic logicmedicine.diseaseLikelihood ratioRheumatologyACR criteriaClinical PracticeEarly DiagnosisRheumatoid arthritisPractice Guidelines as TopicPhysical therapyEmergency MedicineProbabilistic clinical reasoningbusinessRheumatismInternal and emergency medicine
researchProduct

MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

2008

Abstract Background Infliximab is a widely used biological agent for the treatment of inflammatory bowel disease, and has a favorable risk/benefit ratio. Aim It is useful to know that patients treated with infliximab are exposed to developing adverse events that could be reduced with a prudent and a rational clinical approach and by optimizing the treatment protocol. Methods PubMed (including Epub) was searched in October 2006 and again in March 2007. Results The high immunogenic potential of infliximab determines the antibodies that inhibit the effect of infliximab and the appearance of subsequent acute and delayed infusion reactions. Infliximab has an immunomodulatory effect, thus increas…

musculoskeletal diseasesmedicine.medical_specialtyTuberculosisInflammatory bowel diseaseGastroenterologyDrug Administration SchedulePharmacotherapyimmune system diseasesInternal medicinemedicineHumansImmunologic Factorsskin and connective tissue diseasesAdverse effectClinical Trials as TopicHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesInfliximabInfliximabLymphomastomatognathic diseasesHeart failureToxicityDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept

2020

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryDermatologymedicine.diseaseDermatologyToxic epidermal necrolysisInfliximabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child Healthbiology.proteinmedicineTumor necrosis factor alphaLevetiracetamAntibodyskin and connective tissue diseasesbusinessmedicine.drugPediatric Dermatology
researchProduct

Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica.

2021

Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).1 Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).1.

musculoskeletal diseasesmedicine.medical_specialtyeducationImmunologyGiant Cell ArteritisPolymyalgia rheumaticaAbataceptDiagnosis DifferentialRheumatologyRefractoryimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectbusiness.industryAbataceptmedicine.diseaseCombined Modality TherapyPolymyalgia RheumaticaMethotrexatebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugThe Journal of rheumatology
researchProduct

Celecoxib for recurrent sclerouveitis after syphilitic panuveitis. A case report

2011

Purpose To report a case of recurrent ocular inflammation after optimal therapy of bilateral syphilitic panuveitis responding to oral celecoxib. Methods A case report was conducted. Results A 76-year-old man presented with painful blurry vision in both eyes. Ocular examination disclosed bilateral panuveitis. Serological testing confirmed blood and cerebrospinal fluid syphilitic involvement. After 2 weeks of intravenous penicillin therapy, recurrent episodic sclerouveitis was observed. Conclusion Ocular inflammation after healing of infectious uveitis is a rare ophthalmic sequela. In an immunocompetent patient, either re-infection or immune uveitis should be evoked. Non-steroidal therapeutic…

musculoskeletal diseasesmedicine.medical_specialtygenetic structuresbusiness.industryBrief ReportPanuveitisSclerouveitisDermatologyeye diseasesOphthalmologyInfectious DiseasesCelecoxibBilateral syphilitic panuveitisCelecoxibmedicinelipids (amino acids peptides and proteins)heterocyclic compoundsTreponema pallidumskin and connective tissue diseasesbusinessOcular inflammationmedicine.drugJournal of Ophthalmic Inflammation and Infection
researchProduct

Las bibliotecas de dos alfaquíes borjanos.

2000

Labarta Gomez, Ana Maria - Ana.Labarta@uv.es

musculoskeletal diseasesstomatognathic diseasesCultura escritaMoriscosUNESCO::HISTORIAimmune system diseases:HISTORIA [UNESCO]Mudéjares ; Moriscos ; Alfaquíes ; Cultura escritaskin and connective tissue diseasesMudéjaresAlfaquíes
researchProduct

Problemàtica de les inundacions en la conca baixa del riu Gorgos.

1992

Camarasa Belmonte, Ana - Ana.Camarasa@uv.es

musculoskeletal diseasesstomatognathic diseasesRiu Gorgos:GEOGRAFÍA [UNESCO]immune system diseasesXàbiaPaís ValenciàXàbia ; Marina Alta ; País Valencià ; Riu Gorgosskin and connective tissue diseasesUNESCO::GEOGRAFÍAMarina Alta
researchProduct

Myositiden bei Gefäß-Bindegewebskrankheiten

1989

Sammelbezeichnung fur Muskelveranderungen vom Typ der „interstitiellen Myositis“ bei Panarteriitis nodosa, Lupus erythematodes, Sklerodermie, rheumatoider Polyarthritis, Wegener-Granulomatose, Sjogren-Syndrom (Sicca-Komplex) u. a.

musculoskeletal diseasesstomatognathic diseasesintegumentary systemskin and connective tissue diseaseseye diseases
researchProduct

Molecular and Macromolecular Changes in Bottle-Aged White Wines Reflect Oxidative Evolution–Impact of Must Clarification and Bottle Closure

2018

This article is part of the Research Topic "The Chemistry of Wine Ageing" Adresse de correspondance: Institut Universitaire de la Vigne et du Vin, Dijon, France PMCID: PMC5897750; International audience; Chardonnay wines from Burgundy, obtained from musts with three levels of clarification (Low, Medium and High) during two consecutive vintages (2009 and 2010) and for two kinds of closures (screw caps and synthetic coextruded closures) were analyzed chemically and sensorially. Three bottles per turbidity level were opened in 2015 in order to assess the intensity of the reductive and/or oxidative aromas (REDOX sensory scores) by a trained sensory panel. The chemical analyses consisted in poly…

must clarificationmustsoxidationdigestive oral and skin physiologypolysaccharideswhite winefood and beveragescolloidal contentjuicequantificationsensory analysislcsh:ChemistryChemistryresiduesprefermentation clarificationironlcsh:QD1-999quality[SDV.IDA]Life Sciences [q-bio]/Food engineeringsaccharomyces-cerevisiaemetabolismproteomicOriginal ResearchFrontiers in Chemistry
researchProduct

Explicit behavioral detection of visual changes develops without their implicit neurophysiological detectability

2012

Change blindness is a failure of reporting major changes across consecutive images if separated, e.g., by a brief blank interval. Successful change detection across interrupts requires focal attention to the changes. However, findings of implicit detection of visual changes during change blindness have raised the question of whether the implicit mode is necessary for development of the explicit mode. To this end, we recorded the visual mismatch negativity (vMMN) of the event-related potentials (ERPs) of the brain, an index of implicit pre-attentive visual change detection, in adult humans performing an oddball-variant of change blindness flicker task. Images of 500 ms in duration were prese…

muutossokeuschange blindnessaivojen herätevasteetvisual mismatch negativitygenetic structuresflicker paradigmsense organsskin and connective tissue diseasespoikkeavuusnegatiivisuusevent-related potentialsoddball paradigm
researchProduct